Journal Watch · Signal Transduction and Targeted Therapy · 2026

Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.

Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.

Price JDW, Vizeacoumar FS, Abuhussein O et al.Signal Transduction and Targeted Therapy3 min readPharma relevance 50/100

DOI: 10.1038/s41392-026-02750-0PMID: 42236690Study type: preclinical (animal / model) study

TL;DR

Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.

Key findings

  • Loss of FTSJ3 destabilizes TERRA, disrupts recruitment of the histone methyltransferase SUV39H1, and diminishes H3K9 trimethylation and HP1 assembly at sub-telomeric regions.
  • This breakdown of repressive telomeric chromatin leads to genome instability and apoptosis specifically in hTERT-positive cells.
  • These findings highlight SDL as a powerful strategy for uncovering targetable vulnerabilities and establish FTSJ3 as a central regulator of heterochromatin stability in telomerase-active cancers.
  • Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.

What they did

From these datasets, 100 high-confidence candidates were prioritized and validated using an arrayed in vitro CRISPR screen and a pooled in vivo CRISPR screen across diverse cancer models, non-malignant cells, and patient-derived organoids. Through this pipeline, we identified FTSJ3, an RNA 2'-O-methyltransferase, as a top SDL target of hTERT. Depletion of FTSJ3 selectively impaired the viability of hTERT-positive cancer cells while sparing normal cells. Mechanistically, FTSJ3 installs 2'-O-methylation on the telomeric RNA TERRA, a modification essential for TERRA stability and function.

Full abstract (original)

Background: Tumor heterogeneity presents a major clinical challenge. Reactivation of telomerase (hTERT) is a near-universal hallmark of cancer, yet direct inhibition of hTERT has shown limited therapeutic benefit. To uncover tractable telomerase-related vulnerabilities, we applied a synthetic dosage lethality (SDL) strategy to identify genes required only when hTERT is overexpressed. We performed genome-wide CRISPR/Cas9 and shRNA screens across multiple isogenic cell line pairs differing in hTERT expression.

What they did: From these datasets, 100 high-confidence candidates were prioritized and validated using an arrayed in vitro CRISPR screen and a pooled in vivo CRISPR screen across diverse cancer models, non-malignant cells, and patient-derived organoids. Through this pipeline, we identified FTSJ3, an RNA 2'-O-methyltransferase, as a top SDL target of hTERT. Depletion of FTSJ3 selectively impaired the viability of hTERT-positive cancer cells while sparing normal cells. Mechanistically, FTSJ3 installs 2'-O-methylation on the telomeric RNA TERRA, a modification essential for TERRA stability and function.

Results & conclusions: Loss of FTSJ3 destabilizes TERRA, disrupts recruitment of the histone methyltransferase SUV39H1, and diminishes H3K9 trimethylation and HP1 assembly at sub-telomeric regions. This breakdown of repressive telomeric chromatin leads to genome instability and apoptosis specifically in hTERT-positive cells. These findings highlight SDL as a powerful strategy for uncovering targetable vulnerabilities and establish FTSJ3 as a central regulator of heterochromatin stability in telomerase-active cancers. Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.

Abstract © the authors / Signal Transduction and Targeted Therapy (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41392-026-02750-0 · PubMed 42236690.

Why it matters for pharma & biotech

  • Directly relevant to teams in gene editing — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: gene editing

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Signal Transduction and Targeted Therapy study find?

Targeting FTSJ3 enzymatic activity offers a promising therapeutic entry point, acting upstream of TERRA to eliminate telomerase-driven malignancies selectively.

What type of study is this?

It is a preclinical (animal / model) study, published in Signal Transduction and Targeted Therapy in 2026. From these datasets, 100 high-confidence candidates were prioritized and validated using an arrayed in vitro CRISPR screen and a pooled in vivo CRISPR screen across diverse cancer models, non-malignant cells, and patient-derived organoids.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41392-026-02750-0. PubMed ID: 42236690. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Price JDW, Vizeacoumar FS, Abuhussein O et al.. Epigenetic control of telomeric RNA maintains heterochromatin in telomerase-driven cancers.. Signal Transduction and Targeted Therapy (2026). DOI: 10.1038/s41392-026-02750-0.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/epigenetic-control-of-telomeric-rna-maintains-heterochromatin-in-telomer-027500/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides